What is the quality of evidence of the meta-analysis that compared dual RASi with mono RASi?
The overall quality of the evidence of the meta-analysis that compared dual RASi with mono RASi was moderate due to concerns regarding inconsistency for all-cause mortality and CV events and serious imprecision for ESKD due to wide CIs that indicated appreciable benefits and harms (Supplementary Table S32).169 The ERT review (including Cochrane reviews that were updated259,281 ) rated the quality of evidence to be moderate for studies that compared dual with mono RASi because of study limitations, with unclear reporting for Cochrane risk of bias282 domains, random sequence generation, and allocation concealment (Supplementary Table S31234,277 279,283,284 ).